List view / Grid view
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
Using a combination of Cas9 and Cas12a, Canadian researchers have enabled CRISPR methods to edit multiple genes at the same time.
Researchers have developed a new screening technique by inactivating the molecular structure of the human muscarinic receptor, allowing them to test potential drugs.
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.
Researchers have developed a highly sensitive technique for probing molecules that they say could enable new applications in the fields of spectroscopy.
A novel 4D printer has been created which can combine organic chemistry, surface science and nanolithography to design surfaces with organic or biological molecules for drug research.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
A study has shown that using a particular three-stranded structure can extend the catalytic performance of artificial metalloenzymes.
Using fluorescent markers, researchers have developed Förster resonance energy transfer (FRET) to image the assembly, functions and interactions of molecules.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
Researchers have applied for a patent for their innovative cantilever and vibrating plate technique which they say could increase the speed of atomic force microscopy on fragile samples.
Scientists have shown an innovative new biomaterial made of graphene oxide and proteins could be used to 3D print model vascular structures.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
